CN1793350A - 猪凝血酶的制备方法 - Google Patents
猪凝血酶的制备方法 Download PDFInfo
- Publication number
- CN1793350A CN1793350A CN 200510010518 CN200510010518A CN1793350A CN 1793350 A CN1793350 A CN 1793350A CN 200510010518 CN200510010518 CN 200510010518 CN 200510010518 A CN200510010518 A CN 200510010518A CN 1793350 A CN1793350 A CN 1793350A
- Authority
- CN
- China
- Prior art keywords
- pig
- preparation
- thrombiase
- former
- precipitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 210000004556 brain Anatomy 0.000 claims abstract description 15
- 229940088598 enzyme Drugs 0.000 claims abstract description 15
- 210000002381 plasma Anatomy 0.000 claims abstract description 14
- 108090000190 Thrombin Proteins 0.000 claims abstract description 13
- 229960004072 thrombin Drugs 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 56
- 108010064129 Thrombogen Proteins 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004255 ion exchange chromatography Methods 0.000 claims description 8
- 229940006612 barium citrate Drugs 0.000 claims description 7
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 6
- 102000008946 Fibrinogen Human genes 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 229940012952 fibrinogen Drugs 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- -1 polyoxyethylene Polymers 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 238000013096 assay test Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 238000003795 desorption Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 108010014172 Factor V Proteins 0.000 claims description 2
- 108010014173 Factor X Proteins 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 5
- 241000283690 Bos taurus Species 0.000 abstract 2
- 101000651441 Sus scrofa Prothrombin Proteins 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 14
- 238000011160 research Methods 0.000 description 8
- 235000015278 beef Nutrition 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000000025 haemostatic effect Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010051937 Osteorrhagia Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 206010052535 Small intestinal haemorrhage Diseases 0.000 description 1
- 241000173347 Tonsilla Species 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100105184A CN100383241C (zh) | 2005-11-11 | 2005-11-11 | 猪凝血酶的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100105184A CN100383241C (zh) | 2005-11-11 | 2005-11-11 | 猪凝血酶的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1793350A true CN1793350A (zh) | 2006-06-28 |
CN100383241C CN100383241C (zh) | 2008-04-23 |
Family
ID=36805000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100105184A Expired - Fee Related CN100383241C (zh) | 2005-11-11 | 2005-11-11 | 猪凝血酶的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100383241C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104073477A (zh) * | 2013-03-29 | 2014-10-01 | 宿松县春润食品有限公司 | 一种低成本、工业化分离猪凝血酶原的方法 |
CN105985940A (zh) * | 2015-02-06 | 2016-10-05 | 广州倍绣生物技术有限公司 | 用于制备凝血酶的方法 |
CN107727872A (zh) * | 2017-09-01 | 2018-02-23 | 上海太阳生物技术有限公司 | 一种肝素测定的试剂盒 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102492681A (zh) * | 2011-11-22 | 2012-06-13 | 吉林大学 | 一种利用凝胶分子筛去除猪凝血酶中内毒素的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9503750D0 (en) * | 1995-02-24 | 1995-04-12 | Common Services Agency | Thrombin preparation |
CN1294257C (zh) * | 2004-09-15 | 2007-01-10 | 黄耀江 | 一种制备凝血酶的方法 |
-
2005
- 2005-11-11 CN CNB2005100105184A patent/CN100383241C/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104073477A (zh) * | 2013-03-29 | 2014-10-01 | 宿松县春润食品有限公司 | 一种低成本、工业化分离猪凝血酶原的方法 |
CN105985940A (zh) * | 2015-02-06 | 2016-10-05 | 广州倍绣生物技术有限公司 | 用于制备凝血酶的方法 |
CN105985940B (zh) * | 2015-02-06 | 2021-07-23 | 广州倍绣生物技术有限公司 | 用于制备凝血酶的方法 |
CN107727872A (zh) * | 2017-09-01 | 2018-02-23 | 上海太阳生物技术有限公司 | 一种肝素测定的试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN100383241C (zh) | 2008-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dickinson et al. | Prostaglandin in the saliva of the cattle tick Boophilus microplus | |
US5143838A (en) | Method of producing thrombin from factor ii using calcium ions for the conversion on an anion exchanger | |
Tanzer et al. | Collagen metabolism in the normal and lathyritic chick | |
CN100383241C (zh) | 猪凝血酶的制备方法 | |
JPH05500105A (ja) | 改良された安定な凝固対照 | |
CN101584853B (zh) | 一种地龙蛋白多肽制剂 | |
US4137127A (en) | Process for the preparation of thrombin-like enzymes from snake venoms | |
CN106928344A (zh) | 用于从含有凝血因子的溶液中减少和/或除去FXI和FXIa的方法 | |
US4977246A (en) | High recovery process for antihemophilic factor | |
CN101367865B (zh) | 一种高纯度猪血白蛋白的生产工艺及其应用 | |
CN112342260A (zh) | 一种利用脱脂南极磷虾粉制备降血糖肽的方法及其产品 | |
CN107305172A (zh) | 一种基于疏水基团修饰的蛋白质n-端富集方法 | |
CN1250718C (zh) | 蝰蛇蛇毒血凝酶的层析纯化方法 | |
CN1159438C (zh) | 一种尖吻蝮蛇毒凝血酶及其生产方法 | |
CN1944642A (zh) | 尖吻蝮蛇毒36kd单链血凝酶及其制备方法 | |
CN102146134B (zh) | 一种高效提取纯化凝血因子ix和凝血因子x的方法 | |
US4479937A (en) | Process of treating inflammation with human urinary thiol protease inhibitor | |
CN114957505A (zh) | 一种多糖类胰蛋白酶抑制剂及其制备方法 | |
CN101812436B (zh) | 一种尖吻蝮蛇蛇毒类凝血酶及其制备方法和应用 | |
CN1159437C (zh) | 尖吻蝮蛇毒凝血酶及其生产方法 | |
CN102021160A (zh) | 一种蛇毒丝氨酸蛋白酶、其编码基因及应用 | |
CN114262727B (zh) | 一种地龙中纤溶活性多肽及其制备方法 | |
CN1189559C (zh) | 一种从蛇毒中分离纯化类凝血酶的方法 | |
Moriya et al. | Human salivary kallikrein and liberation of colostrokinin | |
CN1548534A (zh) | 一种蛇毒凝血酶及其生产方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: NORTHEAST AGRICULTURAL UNIVERSITY Free format text: FORMER OWNER: GAO XUEJUN; APPLICANT Effective date: 20060728 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20060728 Address after: 150030 No. 59 Wood Street, Xiangfang District, Heilongjiang, Harbin Applicant after: Northeast Agricultural University Address before: 150030 Heilongjiang Province, Harbin city Xiangfang District Gongbin road Wood Street No. 59 Northeast Agricultural University of biological science and Technology Research Center Applicant before: Gao Xuejun Co-applicant before: Zhang Qiang |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |